# Regadenoson

NDC: 67457-994
Generic name: Regadenoson
Labeler / Manufacturer: Mylan Institutional LLC
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: Abbreviated NDA (generic)
Dosage form: INJECTION
Routes: INTRAVENOUS
Marketing started: 20230921
Marketing ended: 20260630
FDA application: ANDA213856

## Active ingredients

- REGADENOSON: .4 mg/5mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"67457-994"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=67457-994
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e1ab38bf-cfd0-444f-a8a6-bb8588b63228